AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie operating Lease Liabilities — Total [year-end] ($M) ($M)
Form 10-K Leases Note
Latest, FY2025
883
Period ended Dec 31, 2025
Change on a year earlier
+0.9%
875 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Operating Lease Liabilities — Total [year-end] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 883 | +0.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 875 | -2.9% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 901 | -2.1% | Form 10-K (filed 2024-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 920 | +3.3% | Form 10-K (filed 2023-02-17) ↗ |
| FY2021 | Dec 31, 2021 | 891 | -11.5% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 1,007 | +179.7% | Form 10-K (filed 2021-02-19) ↗ |
| FY2019 | Dec 31, 2019 | 360 | – | Form 10-K (filed 2020-02-21) ↗ |
Breakdown
What makes up operating lease liabilities — total [year-end] ($m)
- Operating Lease Right-of-Use (ROU) Assets [year-end] ($M)737 · FY2025
- Operating Lease Liabilities — Current [year-end] ($M)194 · FY2025
- Operating Lease Liabilities — Noncurrent [year-end] ($M)689 · FY2025
- Operating Lease Cost [annual] ($M)213 · FY2025
- Operating Lease Cash Payments [annual] ($M)230 · FY2025
- Operating Lease Weighted-Average Discount Rate (%)3.5% · FY2025
Cite this data
StockData. (2026). AbbVie Operating Lease Liabilities — Total [year-end] ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/op_lease_liab_tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.